Undervalued European Small Caps With Insider Action In August 2026
European markets have shown resilience, with the STOXX Europe 600 Index rising by 1.70% amid firmer risk appetite and robust earnings reports, despite a volatile geopolitical backdrop. As economic activity in the Eurozone shows signs of recovery, particularly in services sectors, investors are increasingly interested in small-cap stocks that may offer growth potential during these dynamic times. In this context, identifying stocks with strong fundamentals and insider activity can be crucial for those looking to navigate the evolving landscape effectively.
Top 10 Undervalued Small Caps With Insider Buying In Europe
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Eurocell | 11.9x | 0.3x | 47.47% | ★★★★★☆ |
| Nederman Holding | 19.1x | 0.8x | 24.54% | ★★★★★☆ |
| Tokmanni Group Oyj | 1978.6x | 0.2x | 37.12% | ★★★★★☆ |
| Bilia | 16.0x | 0.3x | 31.53% | ★★★★☆☆ |
| NoHo Partners Oyj | 16.0x | 0.5x | 31.06% | ★★★★☆☆ |
| Franchise Brands | 27.0x | 2.0x | 47.88% | ★★★★☆☆ |
| Linc | 13.1x | 13.6x | 29.41% | ★★★★☆☆ |
| CellaVision | 28.2x | 4.9x | 41.96% | ★★★☆☆☆ |
| Travis Perkins | NA | 0.3x | -80.85% | ★★★☆☆☆ |
| Samhällsbyggnadsbolaget i Norden | NA | 3.3x | -123.67% | ★★★☆☆☆ |
Let's dive into some prime choices out of from the screener.
Ashtead Technology Holdings (LSE:AT.)
Simply Wall St Value Rating: ★★★★★★
Overview: Ashtead Technology Holdings specializes in providing equipment and services for the oil well industry, with a market cap of approximately £0.36 billion.
Operations: The company generates revenue primarily from oil well equipment and services, with a recent gross profit margin of 74.38%. Operating expenses are a significant cost component, including general and administrative expenses, which were £51.42 million in the latest period.
PE: 10.8x
Ashtead Technology Holdings, a smaller player in Europe's investment landscape, is capturing attention with its potential for growth. Recent insider confidence, shown through share purchases earlier in 2026, suggests optimism about the company's trajectory. Despite relying entirely on external borrowing for funding—a riskier approach without customer deposits—its financial position remains solid. Earnings are projected to grow by 9% annually. Investors await the Q1 2026 earnings release on June 9 for further insights into performance and future prospects.
Inwido (OM:INWI)
Simply Wall St Value Rating: ★★★★★★
Overview: Inwido operates as a leading manufacturer and supplier of windows and doors, with a market capitalization of SEK 8.56 billion.
Operations: The company generates revenue primarily from its regional segments, with Scandinavia contributing the highest at SEK 4.49 billion. Over recent periods, the net income margin has shown variability, reaching a peak of 9.24% in December 2021 and declining to 5.36% by March 2026. Operating expenses consistently include significant allocations to sales and marketing as well as general and administrative costs.
PE: 19.1x
Inwido, a smaller European company, is showing promising signs of growth with recent earnings reports indicating an increase in sales and net income for Q2 2026. Sales rose to SEK 2.72 billion from SEK 2.34 billion the previous year, while net income climbed to SEK 197 million from SEK 156 million. Insider confidence is reflected by Anders Wassberg's significant share purchase valued at approximately SEK 173.68 million between January and July this year, suggesting optimism about future performance despite high debt levels and reliance on external funding sources.
- Navigate through the intricacies of Inwido with our comprehensive valuation report here.
Gain insights into Inwido's historical performance by reviewing our past performance report.
RaySearch Laboratories (OM:RAY B)
Simply Wall St Value Rating: ★★★★☆☆
Overview: RaySearch Laboratories specializes in developing advanced software solutions for radiation therapy used in cancer treatment, with a market capitalization of approximately SEK 5.95 billion.
Operations: RaySearch Laboratories generates revenue primarily through its high gross profit margins, which were 92.42% in Q4 2019 and increased to 92.95% by Q3 2025. The company's cost structure is significantly influenced by operating expenses, with sales and marketing being the largest component, reaching SEK 362.3 million in Q1 2026. R&D expenses are also substantial, amounting to SEK 268.4 million during the same period, highlighting a focus on innovation and development within their financial strategy.
PE: 28.8x
RaySearch Laboratories, a European company specializing in oncology software, has been experiencing mixed financial performance. Recent earnings showed a decline in sales and net income compared to the previous year, with second-quarter sales at SEK 272.3 million and net income at SEK 19.6 million. Despite this, insider confidence is evident as Gunther Marder purchased shares worth approximately SEK 2.8 million recently, indicating belief in the company's potential growth prospects. The firm continues to expand its global footprint with new orders from institutions like UNC for advanced proton therapy capabilities and entry into Vietnam's market via Tam Anh General Hospital's proton therapy system initiative. However, challenges such as postponed deals in the U.S., along with an FDA recall related to RayCare software issues, highlight areas needing attention amidst their ongoing innovation efforts like RayCare v2026 enhancements for integrated cancer care solutions.
- Dive into the specifics of RaySearch Laboratories here with our thorough valuation report.
Evaluate RaySearch Laboratories' historical performance by accessing our past performance report.
Summing It All Up
- Dive into all 51 of the Undervalued European Small Caps With Insider Buying we have identified here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com